Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Wave Life SciencesWVE +2.19%60 3-1 Month Momentum % is -7.43% as of Aug. 21, 2026. GuruFocus rates WVE with a GF Score™ of 60/100 and a GF Value™ of $4.00 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,386 Biotechnology companies, Wave Life Sciences ranks worse than 50.58% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-21), Wave Life Sciences's 3-1 Month Momentum % is -7.43%.
The industry rank for Wave Life Sciences's 3-1 Month Momentum % or its related term are showing as below:
WVE's 3-1 Month Momentum % is ranked worse than 50.58% of 1386
companies
in the Biotechnology industry
Industry Median: -7.01
vs WVE: -7.43
Wave Life Sciences (NAS:WVE) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Wave Life Sciences 3-1 Month Momentum % Related Terms
WVE vs FBRX, SVRA, SPTX: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Wave Life Sciences's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wave Life Sciences 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Wave Life Sciences's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Wave Life Sciences's 3-1 Month Momentum % falls into.
Wave Life Sciences (NAS:WVE) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wave Life Sciences (WVE) has a 3-1 Month Momentum % of -7.43% as of Aug. 21, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Wave Life Sciences and its competitors. According to the industry distribution chart, Wave Life Sciences ranks #701 out of 1386 companies in the Biotechnology industry, placing it in the top 50.6%.
Is Wave Life Sciences' 3-1 Month Momentum % too high?
Wave Life Sciences' current 3-1 Month Momentum % is -7.43%. Based on the distribution chart, Wave Life Sciences ranks #701 out of 1386 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Wave Life Sciences has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Wave Life Sciences' 3-1 Month Momentum % compare to FBRX and SVRA?
According to the Biotechnology industry distribution chart, Wave Life Sciences ranks #701 out of 1386 companies for 3-1 Month Momentum %. This places Wave Life Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Wave Life Sciences and its competitors. Wave Life Sciences's current 3-1 Month Momentum % is -7.43%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wave Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Wave Life Sciences (WVE) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.00, compared to a current price of $5.37 — trading 34.1% above its estimated fair value. The current 3-1 Month Momentum % is -7.43%. Wave Life Sciences' overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Wave Life Sciences (WVE), the current 3-1 Month Momentum % is -7.43% as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wave Life Sciences (WVE) Overvalued in 2026?
Based on GuruFocus' analysis, Wave Life Sciences stock appears to be overvalued.
The current stock price of $5.37 is trading 34.1% above its estimated GF Value™ of $4.00.
GuruFocus considers Wave Life Sciences to be Significantly Overvalued.
Key valuation signals for WVE:
3-1 Month Momentum %: -7.43%
GF Value™: $4.00 vs. price of $5.37 (34.1% above fair value)
No single metric tells the full story. See the WVE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
60GF Score
Get the complete analysis for WVE
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WVE has been successfully added to your 
